PNH and aHUS Market Size, Share, Growth and Industry Analysis by Type (Soliris, and, ultomiris) By Application (PNH, and, aHUS), Regional Insights, and Forecast To 2033

• 

  Request a Free sample to learn more about this report

PNH AND AHUS MARKET OVERVIEW

The PNH And aHUS Market, valued at USD 6.2 billion in 2024, is forecasted to increase to USD 6.6 billion in 2025 and surpass USD 10.84 billion by 2033, expanding at a CAGR of 6.4% from 2025 to 2033.

The PNH (paroxysmal nocturnal hemoglobinuria) and aHUS (atypical hemolytic uremic syndrome) markets have witnessed significant growth in recent years. PNH is a rare hematological disorder characterized by red blood cell destruction, while aHUS are a rare kidney disease causing microvascular damage. The development of targeted therapies and advancements in diagnosis have fueled market expansion. Key players in the industry are investing in research and development to introduce innovative treatments, thus catering to the unmet medical needs of patients worldwide.

Regulatory initiatives and orphan drug designations have incentivized pharmaceutical companies to invest in research and development, leading to the development of innovative therapies for PNH and aHUS. All of the above-mentioned factors will propel the growth of the PNH and aHUS market share.

PNH AND AHUS MARKET SHARE FACT AND FIGURES

Regional Breakdown

• North America holds 45% market share (USD 2.79 billion) with a 6.8% CAGR. Growth factor: Strong healthcare infrastructure, high incidence rates of PNH and aHUS, and the dominance of Soliris and Ultomiris in the market.

• Asia-Pacific holds 25% share, or USD 1.55 billion in 2024, with a growth rate of 7.2% CAGR. Growth factor: Rising awareness of rare diseases and increasing healthcare spending in countries like Japan, China, and India.

• Europe holds 20% of the market, primarily in Germany, France, and Italy, with a 6.2% CAGR. Growth factor: Early adoption of new therapies like Ultomiris and Soliris, with a focus on improving patient outcomes in the region.

• Rest of the World holds around 10% of the global market, equating to USD 0.62 billion in 2024. Growth factor: Expanding healthcare access and growing pharmaceutical industry in Latin America, the Middle East, and Africa.

Product Segments Breakdown

• Soliris dominates the market with approximately 70% of sales, amounting to about USD 4.34 billion in 2024, with a 5.8% CAGR. Growth factor: Established treatment for PNH and aHUS, particularly in the North American and European markets.

• Ultomiris holds around 30% of the market, or about USD 1.86 billion in 2024, growing at 8.3% CAGR. Growth factor: Growing adoption as a next-generation therapy for PNH and aHUS, offering longer dosing intervals and better patient compliance.

COVID-19 IMPACT

Increased Focus on Finding Cure for Coronavirus During Pandemic Decreased Market Growth

The pandemic of COVID-19 was the reason for imposing lockdowns and social distancing rules in order to avoid the risk of rapid spreading of the virus. The COVID-19 pandemic has had a significant impact on the management and care of patients with PNH (paroxysmal nocturnal hemoglobinuria) and aHUS (atypical hemolytic uremic syndrome). The outbreak has disrupted healthcare systems, leading to challenges in access to medical facilities and treatments for these rare diseases.

The increased focus on managing COVID-19 patients has diverted resources from other conditions, including PNH and aHUS. Additionally, individuals with PNH and aHUS may be at a higher risk of severe complications if they contract COVID-19 due to their compromised immune systems. The market experienced a downfall during the pandemic period.

LATEST TRENDS

Development of Targeted Therapies to Accelerate Market Growth

In recent years, there have been several notable innovations in the field of PNH (paroxysmal nocturnal hemoglobinuria) and aHUS (atypical hemolytic uremic syndrome) that have improved patient care. One significant advancement is the development of targeted therapies, such as monoclonal antibodies, which specifically target the underlying mechanisms of these diseases. These therapies have demonstrated promising results in clinical trials, providing better control of symptoms and reducing complications.

Furthermore, advancements in genetic testing and diagnosis have facilitated early detection and personalized treatment approaches. Additionally, there is ongoing research exploring novel therapeutic modalities, including gene therapy and complement inhibitors, which hold potential for further advancements in managing PNH and aHUS. All of these are considered as the latest trend in the market.

Request a Free sample to learn more about this report

PNH AND AHUS MARKET SEGMENTATION

By Type

The market can be divided on the basis of type into the following segments:

Soliris, and, ultomiris. The soliris segment is anticipated to dominate the market during the forecast period.

By Application

Classification based on application into the following segment:

PNH, and, aHUS. The PNH segment is predicted to dominate the market during the research period.

DRIVING FACTORS

Incorporation of Improved Diagnostic Techniques to Fuel Market Growth

Several driving factors contribute to the growth and development of the PNH (paroxysmal nocturnal hemoglobinuria) and aHUS (atypical hemolytic uremic syndrome) markets. Firstly, increased awareness and improved diagnostic techniques have led to better identification and understanding of these rare diseases, resulting in more accurate prevalence estimates.

Secondly, advancements in research and development have led to the introduction of targeted therapies, enhancing treatment options and improving patient outcomes. Additionally, rising healthcare expenditure, favorable reimbursement policies, and increasing investments by key market players have further propelled market growth. Also, the collaborations between pharmaceutical companies and research organizations have accelerated the development of novel therapies, driving the expansion of the PNH and aHUS market.

Growing Awareness Among Healthcare Professionals Regarding Such Syndromes to Propel Market Growth

In addition to the aforementioned factors, several other driving forces contribute to the growth of the PNH (paroxysmal nocturnal hemoglobinuria) and aHUS (atypical hemolytic uremic syndrome) markets. One such factor is the increasing prevalence of these diseases, which is attributed to improved diagnostic techniques and growing awareness among healthcare professionals. Moreover, patient advocacy groups and organizations play a crucial role in raising awareness and advocating for better access to treatments. Technological advancements in healthcare, including genetic testing and next-generation sequencing, have facilitated early detection and personalized treatment approaches. Furthermore, regulatory initiatives and orphan drug designations have incentivized pharmaceutical companies to invest in research and development, leading to the development of innovative therapies for PNH and aHUS. All of the above-mentioned factors are contributing towards the rapid growth and development of PNH and aHUS market growth.

RESTRAINING FACTORS

High Cost of Targeted Therapies and Treatment Regimens to Decrease Market Growth

While there are various driving factors, several restraining factors can impede the growth of the PNH (paroxysmal nocturnal hemoglobinuria) and aHUS (atypical hemolytic uremic syndrome) markets. One significant restraint is the high cost of targeted therapies and treatment regimens, which can limit access for patients and healthcare systems. Limited awareness among healthcare professionals and delayed diagnosis pose additional challenges in providing timely and appropriate care.

The rarity of these diseases also hinders the recruitment of patients for clinical trials and the accumulation of sufficient real-world evidence. Moreover, the regulatory complexities associated with drug development and approval processes can create barriers to market entry for potential therapies. All of these factors can bring down the market growth and development.

• Request a Free sample to learn more about this report

•  

PNH AND AHUS MARKET REGIONAL INSIGHTS

North America to Dominate Market Share in Upcoming Years

The leading region for the management and treatment of PNH (paroxysmal nocturnal hemoglobinuria) and aHUS (atypical hemolytic uremic syndrome) is generally determined by factors such as healthcare infrastructure, research and development activities, and market access. Currently, North America stands out as a prominent region for these rare diseases, with a well-established healthcare system, advanced diagnostic capabilities, and a high level of awareness among healthcare professionals.

several countries in this region have specialized centers and expertise in managing PNH and aHUS. Moreover, increasing focus on rare diseases in emerging markets, is likely to enhance access to diagnosis and treatment options, making them potential future leaders in addressing PNH and aHUS challenges.

KEY INDUSTRY PLAYERS

Leading Players adopt Acquisition Strategies to Stay Competitive

Several players in the market are using acquisition strategies to build their business portfolio and strengthen their market position. In addition, partnerships and collaborations are among the common strategies adopted by companies. Key market players are making R&D investments to bring advanced technologies and solutions to the market.

List of Top PNH and aHUS Companies

• Alexion Pharmaceuticals (U.S.)
• Alnylam Pharmaceuticals (U.S.)
• Omeros Corporation (U.S.)

REPORT COVERAGE

The report provides an insight into the industry from both the demand and supply sides. Further, it also gives information on the impact of COVID-19 on the market, the driving and the restraining factors along with the regional insights. Market dynamic forces during the forecast period have also been discussed for the better understanding of the market situations